Johnson & Johnson has secured U.S. Food and Drug Administration approval for a combination of teclistamab-cqyv (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. The decision, announced on March 5, 2026, is grounded in Phase 3 MajesTEC-3 data that showed statistically significant improvements in both progression-free survival and overall survival versus investigator’s choice standard-of-care regimens.

How the MajesTEC-3 data resets the bar for early relapse treatment in multiple myeloma

The MajesTEC-3 results are not easy to dismiss. An 83% reduction in the risk of disease progression or death against active comparator regimens, with a three-year progression-free survival rate of 83% versus 30% in the control arm, represents a departure from the incremental gains that have characterised recent myeloma approvals. What elevates this beyond headline statistics is that the comparators were not placebo arms. Patients in the control group received daratumumab and dexamethasone with either pomalidomide or bortezomib, which are themselves established, active regimens. Beating standard of care at this magnitude, across a three-year follow-up horizon, is clinically unusual.

The overall survival benefit sharpens that picture. A hazard ratio of 0.46 for OS, with 83.3% of patients in the combination arm alive at three years compared to 65.0% in the control group, is a result that clinicians tracking the field will find difficult to set aside. Overall survival improvements are harder to achieve and more consequential than PFS gains alone, particularly in a disease where sequential therapy lines are the norm and earlier treatment choices determine what remains available later.

The depth of response data reinforces the durability argument. Complete response rates of 81.8% versus 32.1% in the control arm, and minimal residual disease negativity in 58.4% of patients compared to 17.1% in controls, suggest the combination is not merely delaying progression but achieving a level of tumour clearance that structurally different from prior-generation regimens. Whether MRD negativity at these rates translates into long-term functional cure in a meaningful proportion of patients is a question the ongoing study may eventually answer, though the current data are not designed to support that claim.

What the second-line positioning actually changes for the treatment landscape

The commercial and clinical significance of this approval rests largely on the second-line access point. Bispecific T-cell engager therapies have historically entered the market as late-line options, partly because of safety complexity and partly because earlier evidence packages were either not designed or not yet mature enough to support earlier positioning. Teclistamab’s original 2022 accelerated approval required at least four prior lines of therapy. The MajesTEC-3-supported label now enables use after a single prior line.

That shift has direct implications for how oncologists and community-based practices think about sequencing. Multiple myeloma treatment has long operated on the assumption that later-line bispecifics and CAR-T therapies are reserved for patients who have exhausted lenalidomide, bortezomib, and anti-CD38 antibody exposure. A combination that incorporates daratumumab (itself an anti-CD38 antibody) alongside a BCMA-directed bispecific, approved from the second line onward, compresses the conventional sequencing model. Patients arriving at relapse after initial treatment with a lenalidomide-based or bortezomib-based regimen may now be candidates for what has traditionally been considered an advanced-line modality.

For the broader competitive landscape, this creates pressure on other BCMA-directed and CD38-directed combinations in development. Clinical teams at companies advancing rival bispecific antibody programs or next-generation anti-CD38 combinations will be comparing their trial designs and endpoint timelines against a bar that has now moved substantially earlier in the treatment continuum.

Why the safety profile is more complex than the approval framing suggests

The safety data from MajesTEC-3 deserve direct scrutiny, because the aggregate Grade 3/4 adverse event rates in the combination arm were comparable to the control arm at 95.1% versus 96.6%. That numerical similarity, while reassuring in terms of overall tolerability equivalence, does not reflect the qualitative differences in toxicity type.

Infection rates in the combination arm were meaningfully higher. Any-grade infections affected 96.5% of patients receiving teclistamab plus daratumumab and hyaluronidase-fihj, with Grade 3/4 infections in 54.1%, compared to 84.1% any-grade and 43.4% Grade 3/4 in the control arm. Serious infections, including opportunistic infections, occurred in 54% of the combination patients. Fatal infections were recorded in 4.6% of patients. These figures are not disqualifying given the therapeutic context, but they underscore that the management burden of this regimen extends well beyond the clinic visit. Immunoglobulin supplementation and infection prophylaxis are structural requirements, not optional adjuncts, and their reliable delivery in community oncology settings is an open question.

Cytokine release syndrome occurred in 60.1% of patients. All cases were Grade 1 or 2, and the step-up dosing schedule used to manage CRS risk is well-established from earlier teclistamab studies. Immune effector cell-associated neurotoxicity syndrome was rare at 1.1%, lower than rates observed with teclistamab monotherapy, which is a meaningful safety signal in the combination’s favour for neurological tolerability. The overall discontinuation rate due to adverse events was low at 4.6%.

Clinicians and payers assessing this regimen will also note that it requires subcutaneous administration infrastructure, ongoing monitoring protocols, and a restricted REMS program that applies to teclistamab across both its monotherapy and combination indications. For academic medical centres with established bispecific antibody programs, these constraints are manageable. For community oncology practices that treat the majority of multiple myeloma patients in the United States, the infrastructure question is real and unlikely to be resolved by the approval itself.

What the regulatory pathway signals about FDA’s posture toward bispecific combinations

The FDA’s handling of the MajesTEC-3 supplemental Biologics License Application reflects a notably favourable regulatory posture. The application received Breakthrough Therapy Designation and was accepted into Real-Time Oncology Review, both of which accelerate the review process. It was also selected for the Commissioner’s National Priority Voucher Pilot Program, a newer mechanism aimed at incentivising innovative therapies. The convergence of all three mechanisms on a single application is uncommon and suggests the agency viewed the MajesTEC-3 data package as sufficiently differentiated to warrant expedited processing.

This approval is also a confirmatory trial outcome. Teclistamab received accelerated approval in 2022 on the basis of single-arm response rate data. The MajesTEC-3 Phase 3 randomised trial, as the confirmatory study, converts that accelerated approval into a full approval and simultaneously expands the label to earlier lines of therapy. That structural feature of the regulatory history matters because it means the evidence base has now been stress-tested against an active comparator over a clinically meaningful follow-up period, rather than relying solely on response rates in a refractory population.

Regulatory watchers will likely observe how this approval influences expectations for other bispecific antibody programs seeking earlier-line positioning. The combination of a mechanistically synergistic partner drug, a randomised Phase 3 design with OS as a secondary endpoint, and a three-year follow-up horizon may become an informal template for what the FDA requires before approving T-cell engager therapies in earlier lines.

Adoption barriers and the gap between approval and access

Johnson & Johnson’s portfolio position in multiple myeloma is unusually comprehensive. Daratumumab-based regimens are already embedded across multiple lines of myeloma therapy, with reported use in more than 618,000 patients worldwide. Teclistamab, since its 2022 approval, has been administered to more than 23,000 patients globally. The combination approval does not require building commercial infrastructure from scratch, which reduces the time from approval to meaningful uptake.

However, the gap between regulatory approval and broad patient access is rarely straightforward in oncology. Reimbursement decisions, prior authorisation frameworks, and payer assessments of cost-effectiveness will shape how quickly the second-line positioning translates into actual prescriptions. The combination involves two biologic agents, both requiring subcutaneous administration under monitoring conditions, and the economics of the regimen relative to existing standard-of-care triplets will attract scrutiny from both private and government payers.

The steroid-sparing design, which replaces dexamethasone with daratumumab as the backbone partner for teclistamab, is a genuine differentiator for patients with diabetes, cardiovascular risk, or a history of steroid intolerance. Whether payers will assign material weight to this quality-of-life advantage in formulary decisions remains to be seen, but clinicians managing elderly or comorbid patients are likely to find it a meaningful consideration.

The patient support program attached to the approval addresses some access navigation concerns, particularly around insurance verification and prior authorisation support, but these programmes are standard commercial infrastructure rather than structural solutions to coverage barriers. Industry observers will be watching whether uptake in community settings matches the academic centre trajectory, given the REMS requirements and infection monitoring obligations that accompany the regimen.

  anti-CD38, BCMA, bispecific antibody, daratumumab, DARZALEX FASPRO, FDA approval, hematology oncology, Janssen, Johnson & Johnson, MajesTEC-3, multiple myeloma, overall survival, progression-free survival, relapsed refractory multiple myeloma, REMS, T-cell engager, teclistamab, TECVAYLI